Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): consultee and commentator coments on the ACD

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Novartis
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Asthma UK
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): British Society for Allergy and Clinical Immunology
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): British Thoracic Society
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Nurses
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Paediatrics and Child Heath
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Pathologists
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): United Kingdom Clinical Pharmacy Association
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Department of Health
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Healthcare Improvement Scotland

This page was last updated: 01 March 2013